Controls serum phosphorus. ANDA 207288, held by Amneal Pharms Co. Sevelamer Carbonate.
As of Nov 16, 2026, ANDA 207288 (Sevelamer Carbonate), held by Amneal Pharms Co, was first approved by FDA on Nov 28, 2017, with 1 approved supplement and 0 published complete response letters.
Sevelamer carbonate tablets are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 28, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sevelamer Carbonate800MG · tablet;oral | Sevelamer Carbonate | Rx |
| Jan 4, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| Nov 28, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters